A. Krämer
Impact in
- Hematology top 5%
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Cancer Research top 10%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 21
- Cancer Diagnosis and Treatment 13
- Cancer-related Molecular Pathways 6
- Hematology 11
- Acute Myeloid Leukemia Research 7
- Co-authors
- Kai Neben (7 shared papers)AD Ho (1 shared paper)Tilmann Bochtler (10 shared papers)Andreas Willer (4 shared papers)Ute Hegenbart (3 shared papers)H. Löffler (3 shared papers)Anthony Dick Ho (4 shared papers)R Hehlmann (2 shared papers)
- Journals
- Leukemia (11 papers)Annals of Oncology (10 papers)American Journal of Hematology (1 paper)Oncogene (1 paper)Blood Cancer Journal (1 paper)
- Partner nations
- GermanyUnited StatesAustralia
In The Last Decade
A. Krämer
35 papers receiving 1.2k citations
A. Krämer's Hit Papers
Peers
Comparison fields: 5 of 95
- Hematology 344
- Cancer Research 192
- Oncology 340
- Genetics 136
- Cell Biology 194
Countries citing papers authored by A. Krämer
This map shows the geographic impact of A. Krämer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Krämer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Krämer more than expected).
Fields of papers citing papers by A. Krämer
This network shows the impact of papers produced by A. Krämer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Krämer. The network helps show where A. Krämer may publish in the future.
Co-authors
The 25 scholars most cited alongside A. Krämer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group Hit paper breakdown → | 2024 | 214 |
| 2 | 2002 | 127 | |
| 3 | 2022 | 108 | |
| 4 | 2017 | 102 | |
| 5 | 2016 | 75 | |
| 6 | 2003 | 66 | |
| 7 | 2002 | 53 | |
| 8 | 2012 | 53 | |
| 9 | 2002 | 51 | |
| 10 | 1998 | 40 | |
| 11 | Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis. | 1994 | 38 |
| 12 | 2017 | 36 | |
| 13 | 2015 | 35 | |
| 14 | 2018 | 32 | |
| 15 | 1999 | 28 | |
| 16 | 2005 | 27 | |
| 17 | 2016 | 15 | |
| 18 | 2017 | 15 | |
| 19 | 2023 | 14 | |
| 20 | 2023 | 13 |
About A. Krämer
A. Krämer is a scholar working on Oncology, Hematology, Cancer Research, Genetics and Pathology and Forensic Medicine, having authored 38 papers that have together received 1.2k indexed citations. Recurring topics across this work include Cancer Diagnosis and Treatment (13 papers), Cancer Genomics and Diagnostics (7 papers), Acute Myeloid Leukemia Research (7 papers), Cancer-related Molecular Pathways (6 papers), Bone Tumor Diagnosis and Treatments (4 papers), Microtubule and mitosis dynamics (4 papers), Tumors and Oncological Cases (4 papers) and Acute Lymphoblastic Leukemia research (3 papers). The work is most often cited by research in Hematology (344 citations), Cancer Research (192 citations), Oncology (340 citations), Genetics (136 citations) and Cell Biology (194 citations). A. Krämer has collaborated with scholars based in Germany, United States and Australia. Frequent co-authors include Kai Neben, AD Ho, Tilmann Bochtler, Andreas Willer, Ute Hegenbart, H. Löffler, Anthony Dick Ho, R Hehlmann, Axel Benner and Stefan Fröhling. Their work appears in journals such as Leukemia, Annals of Oncology, American Journal of Hematology, Oncogene and Blood Cancer Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.